The Gut Microbiome in Parkinson's Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies/Experiment 10/Signature 1
From BugSigDB
Source: Figure 7
Description: Gut microbiome compositional differences in response to the initiation and continuation Levodopa-Carbidopa Intestinal gel (LCIG) therapies at 12months
Abundance in Group 1: increased abundance in LCIG(Levodopa-Carbidopa Intestinal Gel)
| NCBI | Quality Control | Links |
|---|---|---|
| Bacillus | ||
| Prevotella |
Revision editor(s): Bolanle
